Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for ZYME.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 16.67M
March 31, 2026 69.96M
December 31, 2025 5.097M
September 30, 2025 0.3261M
June 30, 2025 9.114M
March 31, 2025 12.18M
December 31, 2024 -6.886M
September 30, 2024 71.89M
June 30, 2024 -19.78M
March 31, 2024 -7.316M
December 31, 2023 1.404M
September 30, 2023 -7.183M
June 30, 2023 -61.38M
March 31, 2023 -138.22M
December 31, 2022 -20.42M
September 30, 2022 -29.87M
June 30, 2022 -21.92M
March 31, 2022 20.57M
December 31, 2021 -1.992M
Date Value
September 30, 2021 40.10M
June 30, 2021 28.86M
March 31, 2021 76.85M
December 31, 2020 43.30M
September 30, 2020 34.60M
June 30, 2020 82.16M
March 31, 2020 -204.77M
December 31, 2019 -88.80M
September 30, 2019 -22.03M
June 30, 2019 63.10M
March 31, 2019 22.00M
December 31, 2018 -35.12M
September 30, 2018 -12.78M
June 30, 2018 -71.66M
March 31, 2018 12.54M
December 31, 2017 -15.49M
September 30, 2017 -2.190M
June 30, 2017 -20.45M
March 31, 2017 6.589M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Theravance Biopharma, Inc. -60.40M
BridgeBio Pharma, Inc. 17.89M
Aprea Therapeutics, Inc. -0.0152M
ACADIA Pharmaceuticals, Inc. -8.529M
Alnylam Pharmaceuticals, Inc. -363.46M